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Animal models have historically played a critical role in the exploration and characterization of disease pathophysiology and
target identification and in the evaluation of novel therapeutic agents and treatments in vivo. Diabetes mellitus disease, commonly
known as diabetes, is a group of metabolic disorders characterized by high blood glucose levels for a prolonged time. To avoid late
complications of diabetes and related costs, primary prevention and early treatment are therefore necessary. Due to its chronic
symptoms, new treatment strategies need to be developed, because of the limited effectiveness of the current therapies. We
overviewed the pathophysiological features of diabetes in relation to its complications in type 1 and type 2 mice along with rat
models, includingZuckerDiabetic Fatty (ZDF) rats, BB rats, LEW1AR1/-iddm rats, Goto-Kakizaki rats, chemically induced diabetic
models, and Nonobese Diabetic mouse, and Akita mice model.The advantages and disadvantages that these models comprise were
also addressed in this review. This paper briefly reviews the wide pathophysiological and molecular mechanisms associated with
type 1 and type 2 diabetes, particularly focusing on the challenges associated with the evaluation and predictive validation of these
models as ideal animal models for preclinical assessments and discovering new drugs and therapeutic agents for translational
application in humans.
1. Background
Diabetes mellitus is well known as a chronic metabolic
disease that is characterized by a relative or absolute lack
of insulin, resulting in hyperglycemia. A variety of com-
plications arises from chronic hyperglycemia such as neu-
ropathy, nephropathy, and retinopathy and increased risk of
cardiovascular disease [1]. The two most common types of
diabetesmellitus are type 1 diabetes (T1D) and type 2 diabetes
(T2D). Type 1 diabetes is generally thought to be precipitated
by an immune-associated, if not directly immune-mediated,
destruction of insulin-producing pancreatic 𝛽 cells [2, 3].
Therefore, it is considered as an autoimmune disease, and
its occurrence is most common in children and young
adults [4]. The management of the disease via blood glucose
monitoring and exogenous insulin administration is arduous
and costly, which in parallel with the meticulous efforts to
regulate blood glucose can result in hyper- and hypoglycemic
events associated with systemic comorbidities [5, 6]. Type
2 diabetes (T2D) is associated with insulin resistance and
a lack of adequate compensation by the beta cells which
lead to a relative insulin deficiency [7]. Therefore, both
types of endocrine disorders represent quite complex diseases
with the involvement of different bodily systems. On this
basis, animal models should be carefully selected for diabetes
investigations depending on what aspects of the disease are
being studied. Furthermore, animal models play a vital role
in the understanding of diabetes pathogenesis as they allow
the combination of genetic and functional characterization of
the syndrome [8]. Attaining deficiency in insulin production
in type 1 diabetes mellitus can occur by a variety of different
mechanisms ranging from chemical ablation of the beta cells
to breeding rodents that spontaneously develop autoimmune
diabetes. Since the animals used to study type 1 diabetes are
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Figure 1: Summary of animal models of diabetes mellitus.
highly inbred with a limited number of pathways to T1D, the
relevance to human T1D has been questioned [9]. In type
2 diabetes (T2D) mellitus, numerous animal models have
been developed for understanding the pathophysiology of
diabetes and its complications [10].These animalmodels tend
to include models of insulin resistance and/or models of beta
cell failure.On the other hand, several T2D animalmodels are
obese, reflecting the human conditionwhere obesity is closely
linked to T2D development. Most of these models tend to
have abnormalities in a single gene or multiple genes related
to obesity, glucose intolerance, and/or insulin resistance
leading to high blood glucose levels [11]. The outgrowth and
progression of diabetic complications are affected by various
factors including obesity, insulin resistance, hyperglycemia,
and hyperlipidemia [10] (Figure 1).
2. Zucker Diabetic Fatty (ZDF) Rats
Thediscovery of this type of rats occurred in 1961 after a cross
ofMerck (M-strain) and Sherman rats.They are characterized
by a mutated leptin receptor that induces hyperphagia and
the rats become obese by 4 weeks of age [12]. These rats are
hyperinsulinemic, hyperlipidemic, and hypertensive as well
and show impaired glucose tolerance [13]. The homozygous
mutation (fa/fa) of the leptin hormone receptor results in
the development of type 2 diabetes in male rats when
they are fed a high-energy rodent diet. These rats develop
advanced insulin resistance and glucose intolerance between
3 and 8 weeks of age and turn overtly diabetic between
8 and 10 weeks of age with glucose levels in the feeding
state typically 500mg/dL by 10 to 11 weeks of age. Evidence
suggests that there is a good consistency between the increase
in islet DNA content and serum insulin levels indicating
that islet hyperplasia plays a role in the development of
hyperinsulinemia in Zucker Diabetic Fatty (ZDF) rats [14].
Triglycerides and cholesterol levels in obese rats are
higher than those observed in lean rats. The lipotoxicity
is attributed to the products of excessive non-𝛽-oxidative
metabolism of fatty acid excess in skeletal muscle and pan-
creatic islets [15–17]. The common complications of obesity,
insulin resistance, cardiovascular disease, and diabetes are
believed to be caused by high levels of these metabolic
products through disrupting cell function and ultimately
by promoting programmed cell death “lipoapoptosis” [16,
17]. In addition, it was reported that very high lipid levels
can be induced in obese Zucker Diabetic Fatty (ZDF) rats,
using high saturated fat and sucrose-containing diets. The
infertility of obesemales is considered an important issue that
hampers research in these rats and which has been addressed
by the use of testosterone propionate (TP) [18]. Depending
on the amount and duration of TP administration, male
obesity increases the probability of ejaculation and sexual
activity. Furthermore, ZDF rats do not develop hypertension
or cardiovascular disease spontaneously [19].
The inbred Zucker Diabetic Fatty (ZDF) rats substrain
with a diabetogenic phenotype is derived by the induction
of a mutation in this strain. This derived strain of rats are
less obese than the Zucker Fatty (ZF) rats but have more
severe insulin resistancewhich they are unable to compensate
for due to the increase in apoptosis levels in beta cells [20].
This is characterized by initial hyperinsulinemia at eight
weeks of age followed by decreased insulin levels [21]. It was
mentioned that females do not develop overt diabetes [13].
According to these facts, the evolution of diabetes in male
leptin receptor-deficient ZDF rats (ZDF/CrlCrlj) has become
a popular model for preclinical studies of type 2 diabetes due
to the fact that these rats exhibit disrupted islet architecture,
B cell degranulation, and increased B cell death [19].
3. BB Rats
This type of rat was derived from outbredWistar rats. Firstly,
spontaneous autoimmune diabetes was identified in 1974 in a
Canadian colony and then led to the creation of two founder
colonies from which all substrains have been derived includ-
ing one of inbred Biobreeding Diabetes-Prone/Worcester
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(BBDP/Wor) and one of outbred Biobreeding Diabetes-Prone
(BBDP) rats [22]. It was reported that immunologically and
genetically distinct BB rat substrains were derived from
several tertiary Biobreeding (BB) rat colonies [23] including
Biobreeding/Ottawa Karlsburg (BB/OK) (BB/Pfd) and Bio-
breeding Spontaneously Hypertensive Rats (BB.SHR) [24–27].
Additionally, BB rats resistant to diabetes have been bred to
act as controls.
After puberty,Biobreeding (BB) rats develop diabetes with
a similar incidence between males and females with about
90% of rats developing diabetes between eight and sixteen
weeks of age. The diabetic phenotype is quite severe and is
characterized by development of hyperglycemia, hypoinsu-
linemia weight loss, and ketonuria requiring insulin therapy
for survival. The latter clinical and metabolic symptoms are
preceded by histological abnormalities in the islets of pan-
creas. It was concluded that the earliest detectable anomaly is
the enhanced expression of interferon-𝛼 (IFN-𝛼) and major
histocompatibility complex (MHC) class I molecules in islet
cells, which occur soon after weaning followed by progressive
infiltration of islets by macrophages, natural killer (NK) cells,
dendritic cells, T cells and to a lesser extent B cells [28–30].
Though these animals have insulitis with the presence
of T cells, B cells, macrophages, and natural killer (NK)
cells, they are lymphopenic with a severe reduction in CD4+
T cells and a near absence of CD8+ T cells. Lymphopenia
is not a characteristic of type 1 diabetes (T1D) neither in
humans nor in Nonobese Diabetic (NOD) mice. Recently, a
novel member of the GTPase family was described as rIAN5
in the BB rat, and its mutation, which was identified in the
Gimap5 (Ian5) gene (RNO4), results in T cell lymphopenia
causing diabetes in this model [31, 32]. Consequently, it is
perceived as a disadvantage in using Biobreeding (BB) rats
as a model of human type 1 diabetes [22]. T lymphopenia
is present at birth and its severity explains why this ani-
mal is immune-deficient. Although the serum of BB rats
contains normal levels of circulating immunoglobulins and
autoantibodies of various specificities, their capability to
generate germinal centers following immunization with T-
dependent antigens is compromised and the ability of T cells
to generate allospecific cytotoxic T cells and to proliferate
robustly in response to alloantigens in vitro is severely
reduced [33–36]. Otherwise, the advantages of this model
have been insufficient in elucidating type 1 diabetes (T1D)
on the genetic level [37]. In some intervention studies and
studies of diabetic neuropathy, BB rats have been used as
well [38–40]. Both sexes of inbred Biobreeding Diabetes-
Prone/Worcester (BBDP/Wor) rats and outbred Biobreeding
Diabetes-Prone (BBDP) rats develop pancreatic insulitis that
is rapidly followed by selective destruction of beta cells
and frank diabetes between 50 and 90 days of age. The
natural course of insulitis in the spontaneously diabetic BB
rat was noted to be different from that of the Nonobese
Diabetic (NOD) mouse. In Biobreeding (BB) rats, insulitis
is morphologically similar to what is observed in human
T1D and features a predominance of Th1-type lymphocytes
[41, 42]. Profound T cell lymphopenia is shown clearly to
be the most obvious and problematic immunopathology
in all diabetic Biobreeding (BB) rats [43–45]. The rats also
appear to be severely deficient in ART2+ T cells, where ART2
is a rat maturational T cell alloantigen with nicotinamide
adenine dinucleotide glycol-hydrolase activity that appears
to identify cells with immune-regulatory properties [46].
The conditions that lead to beta cell autoreactivity in the
spontaneously diabeticBB rat are still not resolved yet, but the
mechanism likely involves the presentation of autoantigen by
RT1u molecules, while the identity of the primary autoantigen
is unknown. The transfusion of CD4+ ART2+ T cells to
overcome the effects of lymphopenia is considered to be one
of the unique preventative strategies against the spontaneous
diabetic BB rat model [47] with no documented human
equivalent of the ART2+ T cell. The treatment of diabetic BB
rats has been achieved with islet transplantation plus either
immunosuppression [48] or costimulatory blockade [49].
4. LEW 1AR1/-iddm Rats
4.1. (ZDF-Lepr𝑓𝑎/Crl). This rat model of type 1 diabetes
(T1D) arose spontaneously in a colony of congenic Lewis
rats characterized by a defined MHC haplotype Lewis.1AR1
(LEW.1AR1) rat. It is a unique model for studying human
T1D in which rats were being bred in Hannover Medical
School (Ztm) at the Institute of Laboratory Animal Science
and obtained as a result of a spontaneous mutation in the
LEW.1AR1 strain. It was obvious that these rats develop
diabetes between 60 and 90 days of age and are characterized
by rapid progression of insulitis leading to extensive 𝛽
cell destruction [50, 51]. These rats are distinct from the
well-characterized Nonobese Diabetic (NOD) model of T1D
as, unlike Biobreeding Diabetes-Prone (BBDP) rats, diabetes
develops with equal frequency in both male and female
animals [52]. Studies clearly showed that the incidence of
diabetes in these animals is increased from 20% to 60%
with further inbreeding with equal incidence in both genders
[50, 51]; moreover, the animals also display a prediabetic state
that lasts for approximately a week with islet infiltration [51].
The Lewis-insulin dependent diabetes mellitus (LEW-iddm)
rats are able to survive well after diabetes is overtly shown
and, consequently, they can be used as a model to study
diabetic complications [53]. These animals are ketonuric,
but they are not lymphopenic expressing normal numbers
of ART2+ T cells. Furthermore, 𝛽 cells of the islets of
Langerhans of affected animals are infiltrated with B and T
lymphocytes, macrophages, and natural killer (NK) cells and
it appears that the beta cells die via apoptosis [22].They show
apoptotic beta cell destruction induced by proinflammatory
cytokines that are released from islet-infiltrating immune
cells [51]. In Lewis.1AR1-insulin dependent diabetes mellitus
(LEW.1AR1-iddm) rat, the diabetic syndrome displays an
autosomal recessive mode of inheritance with an incomplete
penetrance of the mutant phenotype of about 60% [50, 51].
The genome-wide linkage analysis using a (BN6LEW.1AR1-
iddm) × LEW.1AR1-iddm] N2 (N2 BN) population facilitated
the discovery of three T1DM susceptibility loci in this rat
model [54]. One of these loci mapped to RNO20p12 within
the MHC region provides T1D mellitus susceptibility also
in humans (IDDM1) and the NOD mouse (idd1) and the BB
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rat and the Komeda diabetes-prone (KDP) rat models insulin
dependent diabetes mellitus1 (Iddm1) [8]. In this case, the
MHC haplotype plays a pivotal role in permitting T1DM
development [55]. It was possible to confer protection against
diabetes through adoptive transfer of immune cells from the
Lewis.1AR1 (LEW.1AR1) background strain into prediabetic
LEW.1AR1-iddm rats. Thus, LEW.1AR1 rats are protected
against beta cell autoreactive immune cells by the regulatory
elements of the immune system [56]. In addition to the
diabetes-related MHC class II (Iddm1) susceptibility locus,
insulin dependent diabetes mellitus8 (Iddm8) was identified
recently as the site of mutation(s) contributing to disease
susceptibility in the LEW.1AR1 strain [57].
Moreover, in addition to autoimmune diabetes,
Lewis.1AR1-insulin dependent diabetes mellitus (LEW.1AR1-
iddm) rats manifest a second phenotype described as a
“variableCD3+ T cell frequency”which could also bemapped
within the Iddm8 region [8]. So, the mutation in the Iddm8
region confers susceptibility to diabetes as well as to the
variable CD3+ T cell frequency in blood. A previous study
done by Arndt et al. shows that the spontaneous mutation
in the LEW.1AR1-iddm rat was also identified in the Dock8
gene, and this mutation was also shown to be accompanied
by autoimmune diabetes development and a variable CD3+ T
cell frequency in peripheral blood. It is well known that other
mutations in the Dock family can also lead to an imbalance
in the immune system in humans [58–60].
Effective prevention strategies from diabetes require a
combination therapy to target the proinflammatory cytokines
produced in the different immune cell types. Of crucial
importance in this context is the proinflammatory cytokine
tumor necrosis factor-𝛼 (TNF-𝛼) that is expressed in all
immune cell types infiltrating the pancreatic islets in patients
with T1D as well as in the LEW.1AR1-iddm rat model [61,
62]. Fingolimod (FTY720) treatment has been performed
to protect against islet infiltration in the prediabetic and
early diabetic phase in type 1 diabetes, but only in animal
models and not in humans [63, 64]. The clinical benefit of
this immunomodulatory agent is the lack of severe adverse
effects at a dose of 1mg/kg body weight as applied in
diabetes prevention studies in rodent models, including the
LEW.1AR1-iddm (iddm) [65].
The MHC-II RT1-B/Du haplotype is indispensable for
diabetes development in rats, and, in several studies, the con-
genic Lewis (LEW), Lewsi.1AR1 (LEW.1AR1), and Lewsi.1WR1
(LEW.1WR1) strains were selected to compare the frequencies
of immune cell subpopulations in peripheral blood to those
in LEW.1AR1-iddm rats. The LEW.1AR1 (RT1-Aa, RT1-B/Du,
and RT1-Cu) and LEW.1WR1 (RT1-Au, RT1-B/Du, and RT1-
Ca) strains express also theMHC-II RT1-B/Du haplotype, and,
conversely, the original LEW (RT1-Al, RT1-B/Dl, and RT1-Cl)
strain cannot develop diabetes because of the missing RT1-
B/Du haplotype.
5. Goto-Kakizaki Rats
Developing mild hyperglycaemia at an early stage of life,
the Goto-Kakizaki (GK) rat is considered a nonobese model.
This type 2 diabetes (T2D) model originates from Wistar
(W) rat established by repeated inbreeding with Wistar (W)
rats at the upper limit of normal distribution for glucose
tolerance [66, 67] with most likely glucose intolerance due
to impaired 𝛽 cell mass and function on the background
of a polygenic inheritance. Chronic exposure to hyper-
glycemia (glucotoxicity) may further impair 𝛽 cell function
and insulin action and contribute to the development of
hyperglycemia. However, insulin resistance contributionmay
likely be secondary in the development of hyperglycemia
in this model. Goto-Kakizaki (GK) rat pancreatic islets may
develop into the so-called starfish-shaped islets characterized
by disrupted structure with clear fibrosis separating strands
of endocrine cells making the islets resemble the appearance
of a starfish. These changes are not present in the pancreas
of young GK rats but increase in prevalence with aging
[68]. In adult Goto-Kakizaki (GK) rats, total pancreatic 𝛽 cell
mass and pancreatic insulin stores are similarly decreased
by 60% [69, 70]. This alteration in the 𝛽 cell population
cannot be attributed to increased 𝛽 cell apoptosis but is
rather related, at least in part, to marked decrease in 𝛽 cell
replication [71].The onset of a profound alteration in glucose-
stimulated insulin secretion by the GK 𝛽 cell, after weaning,
correlates with the exposure to the diabetic environment.
These changes in the islet function may result, at least in
part, from a loss of differentiation of 𝛽 cells chronically
exposed to even mild chronic hyperglycemia and elevated
plasma nonesterified fatty acids, a process referred to as
“glucolipotoxicity.” According to a previous study conducted
in our laboratory using GK rats as a diabetic model, mea-
surement of oral glucose tolerance test (OGTT) revealed that
blood glucose concentration peaked at 60min after glucose
administration and then began to decrease. Basal blood
glucose level was significantly lower than that after the oral
glucose tolerance test (OGTT) pointing to the impairment of
carbohydrate homeostasis. Furthermore, the study revealed
that hyperglycemia in GK rats can be moderated by exercise,
where exercise promotes the prevention and treatment of type
2 diabetes (T2D) because of the increase in the capacity of the
muscles to capture circulating glucose due to the decreased
intramuscular fat reserves. Running Goto-Kakizaki (GK) rats
displayed a significantly lower fasting blood glucose level
after the 6-week training period. Initial basal glucose level
(0min) was 9.17 ± 0.21mM/L in the sedentary group and
6.82 ± 0.3mM/L in the voluntary running group. Exercise
was associated with a significantly lower blood glucose level
after 60 (20.51 ± 0.58 versus 16.39 ± 0.81mmol/L) and 120
(19.61 ± 0.76 versus 14.58 ± 0.88mmol/L) min of the OGTT
test [72].
6. Chemically Induced Diabetes
Alloxan and streptozotocin (STZ) are considered the most
potent diabetogenic chemicals used in diabetes research so
far [73]. Both chemicals are employed as cytotoxic glucose
analogues that tend to accumulate in pancreatic beta cells
through glucose transporter 2 (GLUT2) [73].


















Figure 2: The mechanism of action of streptozotocin (STZ) in 𝛽 cells.
STZ acts as a nitrosourea analogue, in which there is
linkage between theN-methyl-N-nitrosourea (MNU)moiety
and carbon-2 of hexose [73]. In general, the mode of action
of toxicity of STZ depends on the DNA alkylating activity of
itsmethyl-nitrosoureamoiety [73].The transfer of themethyl
group from STZ to the DNAmolecule causes damage along a
defined chain of events [73] and leads to DNA fragmentation
[73] (Figure 2).
STZ-induced diabetes is of two types: the adult type and
neonatal type. In case of the adult type streptozotocin- (STZ-
) induced diabetes, rats weighing 140 to 300 g underwent
a single streptozotocin (STZ) intraperitoneal injection (45–
70mg/kg) dissolved in 0.1M citrate buffer (pH 4.5) after an
overnight fast. Control rats of the same age received only an
injection of citrate buffer.
A number of studies with STZ-induced diabetes mellitus
reported that diabetes mellitus can improve the recovery
of cardiac function after ischemia-reperfusion [74] along
with decreasing the incidence of arrhythmias [75, 76]. It
was previously contended that the contractile function of
diabetic hearts following ischemia-reperfusion recovered to
a greater extent than that of the control hearts. However,
the magnitude of the preischemic basal contractile func-
tion was significantly reduced in the diabetic hearts [74].
Protein kinase C (PKC) inhibitors were found to restore
the impaired cardiac function in diabetes before ischemia;
however, PKC inhibitors completely abolished protection
against postischemic injury in diabetic hearts [74].This effect
of protein kinase C inhibition in diabetes may be explained
by the decreased phosphorylation of myocardial proteins
(e.g., troponin) [74]. Chen et al. have found that severe
hyperglycemia due to diabetes mellitus induced by STZ
decreases the incidence of arrhythmias and increases coro-
nary flow and expression of heat shock protein 90 (hsp90)
[75]. Nonetheless, the study hypothesized that increased
osmolarity due to severe hyperglycemia is in charge of the
overexpression of heat shock protein 90 (hsp90), which in
turn increases the production of endothelial nitric oxide
(NO) [75]. Furthermore, it was well addressed that dia-
betic hearts are much more resistant to ischemia-induced
arrhythmias compared to nondiabetic controls [76]. It was
also noted that, 4 weeks following streptozotocin (STZ)
treatment, hearts have improved functional recovery after
ischemia-reperfusion in comparison to control hearts and
this functional recovery was associated with the prevention
of hexokinase solubilization during ischemia [77].
Conversely, several published studies indicated that dia-
betesmellitus induced by STZdid not decrease the infarct size
[78–82], with no reduction in the incidence of arrhythmias
[83]. Some studies also reported that STZ-induced diabetes
mellitus even increased the infarct size compared to normal
rats [84–86].
7. Diabetes and Cardioprotective Strategies
It is still not clear whether or not preconditioning can exert a
cardioprotective effect in subjects with diabetes mellitus, and
further studies are needed in this regard. Wu et al. found that
pharmacological preconditioning with ginsenoside Rb1 in
diabetic rats decreased infarct size, while phosphoinositide 3
(PI3) kinase inhibition with wortmannin reverted the cardio-
protective effects of ginsenoside Rb1, which is an indication
that pharmacological preconditioning with ginsenoside Rb1
involved PI3 kinase/Akt signaling in the diabetic hearts [85].
A study by Zhu et al. showed that the infarct size is decreased
in diabetic rats subjected to ischemic preconditioning and
noninvasive limb ischemic preconditioning, and this pro-
tective effect involved the increase in enzymatic activity
of superoxide dismutase as well as increased glutathione
peroxidase activity [87]. Pharmacological preconditioning
with remifentanil decreased the infarct size both in normal
and in diabetic rats and this protection involves antiapoptotic
pathways of survival, including extracellular signal regulated
kinases (ERK); however, pharmacological preconditioning
was less efficient in the case of diabetic hearts [78]. Another
study by Ravingerova´ et al. on isolated hearts taken from rats
suffering from diabetes mellitus induced by a single strepto-
zotocin (STZ) intravenous injection (45mg/kg) showed that
ischemic preconditioning induced an antiarrhythmic effect
only during the chronic stage of diabetes, in contrary to the
acute stage, where ischemic preconditioning did not decrease
the incidence of ischemic arrhythmia.
Several other studies also revealed that diabetes impairs
preconditioning. Similarly, a study by Ji et al. proved that
diabetes impaired preconditioning [81]. Ischemic precondi-
tioning was abolished in STZ-treated rats due to a failure
to increase glucose uptake during reperfusion [81]. It was
6 Journal of Diabetes Research
shown by Vinokur et al. that impaired iron homeostasis
in diabetic heart can lead to failure of preconditioning to
induce myocardial protection [82]. Sharma et al. found that
diabetes mellitus impaired pharmacological preconditioning
by adenosine; however, adenosine transport blockade by
dipyridamole restored the protective effect [86]. Results of
Ajmani et al. suggested that attenuation of cardioprotection
in the diabetic heart may be due to the decrease in ischemic
preconditioning-mediated release of nitric oxide (NO) in
the diabetic myocardium, which may be a result of upreg-
ulating caveolin and the subsequent decrease of endothelial
nitrogen oxide synthase (eNOS) activity [80]. According
to Yadav et al., diabetes mellitus induced attenuation of
cardioprotective effect of ischemic preconditioning through
the activation of glycogen synthase kinase 3-beta (GSK-3𝛽),
due to the impaired protective upstream signaling pathways
and (mPTP) opening during reperfusion [79]. On the other
hand, Tosaki et al. reported that ischemic preconditioning
did not confer antiarrhythmia and antimyocardial stunning
effects in diabetic rats induced by intraperitoneal injection of
STZ (65mg/kg) [83].
Ischemic postconditioning, as another strategy in car-
dioprotection, is abolished by STZ-induced diabetes mel-
litus. According to Ren et al., it was found that ischemic
postconditioning failed to ameliorate the cardiac function
and most likely failed to reduce creatine kinase and cardiac
troponin I release in isolated perfused heart from diabetic
rats. Moreover, it was also revealed in this study that
the decrease in transient receptor potential cation channel
subfamily V member 1 (TRPV1) and the increase in the
expression of calcitonin gene related peptide (CGRP) and
Substance P (SP) in diabetic hearts caused the loss of
the cardioprotective activity of ischemic postconditioning
associated with a failure to increase calcitonin gene related
peptide (CGRP) and Substance P (SP) release [88]. Sevoflu-
rane postconditioning was abolished by chemically induced
diabetes in a rat model and this detrimental effect involved
the impairment of phosphorylation of glycogen synthase
kinase 3-beta (GSK-3𝛽) and its upstream pathways, such
as PI3 kinase/Akt and extracellular signal regulated kinases
(ERK) in diabetes [89]. Najafi et al. indicated that ischemic
postconditioning did not exert a protective effect in diabetic
hearts [90]. Concurrent inhibition of 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (mPTP) may lead to a restoration
of the protective effect of ischemic postconditioning in these
diseased hearts [90].
In case of neonatal type of STZ treatment, 2–4-day-
old neonatal Wistar (W) rats are injected intraperitoneally
with 65–100mg/kg of STZ or its vehicle (ice-cold citrate
buffer) to induce diabetes. Neonatal rats are kept with their
mother during the lactation period until week 4. For lactating
mothers, standard rat chow and tap water were supplied ad
libitum [91]. Type 2 diabetes (T2D) induced by neonatal STZ
treatment can protect the heart against ischemia-reperfusion
[92]. Moreover, preconditioning can furthermore protect the
diabetic heart [92]. Based on a previous study, the recovery of
cardiac function after ischemia-reperfusion and infarct size
was improved in diabetic rats [93].
Alloxan
Inhibition of glucokinase
Inhibition of insulin secretion
ROS formation 
Necrosis of pancreatic 𝛽 cells
Insulin dependent diabetes
Figure 3: The main pathological effects of alloxan.
It is well known that alloxan possesses two pathological
effects: it can selectively inhibit glucose-induced insulin
secretion through the inhibition of glucokinase, the glucose
sensor of the beta cell, and it creates a state of insulin
dependent diabetes by inducing reactive oxygen species
(ROS) formation causing a selective necrosis of beta cells [73]
(Figure 3).
Alloxanwas also shown to induce diabetes in fastingmale
Wistar (W) rats weighing 200–250 g that were given subcuta-
neously 125mg/kg alloxan [94]. Galagudza et al. have found
that diabetic rats for sixweeksweremore resistant to ischemic
damage compared to themyocardiumof healthy animals, and
ischemic preconditioning in animals with diabetes mellitus
was much less effective in limiting infarct size than in control
animals [94]. However, diabetes mellitus induced by alloxan
interferes with the protective effect of postconditioning in
other species [95–97].
8. Nonobese Diabetic Mouse
This type of mouse was first developed at Shionogi Research
Laboratories in Osaka, Japan, in 1974 [98]. Insulitis appears at
around 3rd or 4th week of their age. During this prediabetic
stage, the islets of the pancreas become infiltrated by CD4+
and CD8+ lymphocytes, though natural killer (NK) and B
cells are also present [99]. The infiltration of innate immune
cells into the islets attracts adaptive CD4+ and CD8+ T
cell subsets into the islets starting from approximately 4–
6 weeks of age [100], which are both required for diabetes
development. Insulitis leads to the destruction of beta cells,
while the onset of overt diabetes usually appears when
approximately 90% of the pancreatic insulin is lost at around
10–14 weeks, although diabetes can develop up to 30 weeks
of age.These mice can lose weight rapidly when they become
overtly diabetic and require insulin treatment.
Nonobese Diabetic (NOD) mouse is one of the most
commonly used models to study type 1 diabetes (T1D).
Unlike other models used in autoimmunity studies, this
model can develop spontaneous disease similar to humans.
Several advances in our understanding of the disease arose
from using this model, including the identification of several
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autoantigens and biomarkers that are similar in humans and
enabled the development of therapeutic targets [101]. Both
in NOD mice and in humans, the most important genetic
factor that contributes to T1D susceptibility is the major
histocompatibility complex (MHC) known as insulin depen-
dent susceptibility 1 (idd1) in mice and insulin dependent
diabetes mellitus1 (IDDM1) in humans [102, 103]. In addition,
more than 40 genetic loci discovered in both NOD mice
and humans have been shown to play an important role
in mediating T1D susceptibility, including genes related to
immune system function and regulation as well as pancreatic
beta cell function [104]. The pancreas of Nonobese Diabetic
(NOD) mice is infiltrated by innate immune cells at an early
period of 3 weeks of age. These cells include dendritic cells
(DCs), macrophages and neutrophils [105–107], prior to the
infiltration of the lymphocytes. Identically, these cells are also
found in the human islet infiltrate [108]. According to several
studies, MHC class 2 proteins in NOD mice share structural
similarities to those in humans, which may confer resistance
or susceptibility to the disease in bothNODmice and humans
[109]. The similarity in the genes of type 1 diabetes (T1D)
between NOD mice and humans has been completely useful
in dissecting some mechanisms and pathways behind T1D
[110].Therefore, these animals are believed to be a potentially
suitable model for testing therapies in which modulation
of the autoimmune response is being targeted. However, it
should also be noted that there are a number of effective drugs
in NOD mice, which were shown to be ineffective in humans
[111]. One of the main issues is the time point of intervention
and another difficulty in the translation of therapies tested in
Nonobese Diabetic (NOD) mice is that whereas the pancreas
of NOD can be removed for examination after a study, there
is a deficiency of biomarkers in human peripheral blood
that could be used as evidence to verify the success of the
intervention [112]. There are problems as well in translating
dosing from the Nonobese Diabetic (NOD)mouse to humans
[112]. Diabetes development in the Nonobese Diabetic (NOD)
mouse is associated negatively with microbial exposure.
Therefore, mice should be protected in specific pathogen-free
(SPF) conditions to maintain diabetes incidence. Because of
the differences in gender, the unpredictability of the disease
onset, and the requirement for SPF conditions, this mouse
model is expensive tomaintain as type 1 diabetes (T1D)model
in comparison with the chemically induced diabetic model.
Adoptive transfer was also proved to be useful, where this
strategy is based on the injection of T cells fromdiabeticNOD
mice into nondiabetic recipient mice, causing the recipient
mouse to develop diabetes [113].
9. Akita Mice
The Akita mouse was initially developed in Akita, Japan,
from a C57BL/6NSlc mouse due to a spontaneous mutation
in insulin 2 gene leading to incorrect proinsulin processing.
This mutation caused the aggregation of misfolded proteins
and led, subsequently, to endoplasmic reticulum (ER) stress
(Figure 4).
Normal AKITA mice 
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Figure 4: Akita mice.
Collectively, these alterations resulted in pronounced
insulin dependent diabetes with an onset of 3 to 4 weeks
of age. The resulting rodent model exhibits characteristic
signs, including hyperglycemia, hypoinsulinemia, polyuria,
and polydipsia. The absence of beta cell mass in this mouse
model renders it a valid alternative to STZ-treated mice
in transplantation studies. It has been well utilized as a
model of type 1 diabetes (T1D) macrovascular disease and
neuropathy [114–116]. Likewise, this model is usually used to
investigate potential alleviators of ER stress in the islets. In
this regard, some of the pathological manifestations of type
2 diabetes (T2D) are also visible in the Akita mouse model
[117]. Studies have reported that mice and humans lacking
PERK, a critical component of the ER stress response, develop
spontaneous diabetes mellitus at a very young age taking into
consideration that 𝛽 cells may be especially vulnerable to
endoplasmic reticulum (ER) stress [118].
Akita mice carry the Ins2+/C96Y mutation, a single
nucleotide substitution in the insulin 2 (Ins2) gene. This
mutation causes incorrect folding of the insulin protein,
pancreatic 𝛽 cells toxic injury, and reduced insulin secre-
tion propensity resulting in T1D [119, 120]. The Ins2C96Y
mutation present in the Akita diabetic mouse prevents the
formation of an essential disulfide bond between insulin 2
chains and prevents proper folding and processing of this
protein. The misfolded proinsulin 2 is not secreted and
is retained in the pancreatic 𝛽 cell endoplasmic reticulum
(ER) during its processing in the secretory pathway [121].
Mice carrying the Ins2C96Y mutation develop progressive
diabetes mellitus, a phenotype that probably reflects a holistic
effect rather than just the loss of correctly folded insulin
production by the mutant Ins2 allele. In fact, rodents have
two insulin genes (Ins1 and Ins2) and, interestingly, the
loss of both Ins2 genes copies is fully compensated [122].
Even though newborn Ins2C96Y mutant mice have nor-
mal sized islets of Langerhans that produce an adequate
complement of insulin-producing 𝛽 cells, over time they
undergo a progressive and marked loss of the 𝛽 cell mass.
Apoptosis-mediated loss of these cells correlates with the
development of diabetes mellitus. A key finding was that this
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specific pathophysiological aspect of the Akitamouse can be
reproduced in vitro by expressing high levels of Ins2C96Y,
but not wild-type Ins2, in the 𝛽 Min6 cell line [123]. This
“Akita” polymorphism of insulin 2 gene (Ins2akita) acts in a
dominant-negative manner in Ins2akita/+ mice and leads to
severe hyperglycemia persisting throughout the mouse life
[124]. It is likely, therefore, that the expression of Ins2C96Y
is toxic to islet cells and that the loss of 𝛽 cell mass mediates
hyperglycemia development in theAkitamouse. Studies have
reported that Ins2 Akita mouse is a valid model of diabetic
sympathetic autonomic neuropathy corresponding closely
to the characteristic pathology of other rodent models and
humans [125]. C57BL/6-Ins2+/C96Y mice also had higher
levels of albuminuria and systematic renal pathological
changes. Therefore, the C57BL/6-Ins2 Akita model presents
a number of advantages over the chemically induced STZ
model of diabetes andmay serve as a platform for developing
models of diabetic nephropathy [126]. Nonetheless, protein-
uria is less developed in C57BL/6-Ins2+/C96Y mice and
mesangial expansion is the only reported renal pathological
change. In this regard, Ins2 Akita mice can serve as a model
of diabetes ameliorating the deficiencies encountered in the
STZ treatment in studies of islet transplantation [114]. It was
argued as well that the mouse genetic background might
exert an effect on the development of kidney injury in Akita
mice [120]. One of the drawbacks that marred the utilization
of this animal model is that the Akita mouse has not been
validated by antineuropathic drugs [127]. These mice, for a
reason yet to be identified, show mesangial immunoglobulin
A (IgA) deposits [128]. This deposition is a major factor in
the development of human mesangial proliferative glomeru-
lopathy and, consequently, the lack of clear understanding
of the underlying mechanism of the increase of mesangial
matrix will make these observations of limited value. This
is especially evident in the cases where the key endpoint is
represented by alterations in mesangial volume and matrix
accumulation [129].
10. Conclusions and Future Outstandings
Due to the increase in the prevalence of diabetes mellitus
worldwide, the diabetic rat models are believed to play an
important role in elucidating the pathogenesis of human dia-
betes and its complications, such as retinopathy, nephropathy,
and neuropathy. Moreover, the diabetic rat models are essen-
tial for investigating and developing novel drugs for diabetes
and its complications. All of the rat and mouse models
available to date possess important limitations, despite all
the advantages they offer. Thus, designing better models of
diabetes mellitus (DM) that will allow identification of the
underlying mechanisms or testing of therapeutic interven-
tions, must continue. The best model of diabetes should
have some major criteria such as the following: the model
should have all major pathogenesis of diabetes with other
minor pathogenesis that can be normally found in diabetic
humans, the model should be sensitive to antidiabetic drugs,
and the model needs to be suitable to study the pathogenesis
of disease as well as for routine pharmacological screening
of antidiabetic drugs. Furthermore, the diseased animal
models have contributed to helping scientists and researchers
to better understand the mechanisms of other diseases in
preclinical studies that allowed the screening of drugs and
pharmaceutical agents, but their value in predicting the
effectiveness of treatment strategies in clinical trials has
remained controversial. In this case, more future studies are
needed to investigate the role of the diseases animals in
combination with pharmacological therapy.
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